Roger S. Lo

33.6k total citations · 9 hit papers
70 papers, 14.2k citations indexed

About

Roger S. Lo is a scholar working on Molecular Biology, Oncology and Computational Theory and Mathematics. According to data from OpenAlex, Roger S. Lo has authored 70 papers receiving a total of 14.2k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Molecular Biology, 41 papers in Oncology and 13 papers in Computational Theory and Mathematics. Recurrent topics in Roger S. Lo's work include Melanoma and MAPK Pathways (38 papers), Computational Drug Discovery Methods (13 papers) and TGF-β signaling in diseases (9 papers). Roger S. Lo is often cited by papers focused on Melanoma and MAPK Pathways (38 papers), Computational Drug Discovery Methods (13 papers) and TGF-β signaling in diseases (9 papers). Roger S. Lo collaborates with scholars based in United States, Australia and United Kingdom. Roger S. Lo's co-authors include Joan Massagué, Stacy W. Blain, Antoni Ribas, Xiangju Kong, Hubing Shi, David Wotton, Jeffrey A. Sosman, Willy Hugo, Richard C. Koya and Akiko Hata and has published in prestigious journals such as Nature, Cell and Journal of Biological Chemistry.

In The Last Decade

Roger S. Lo

66 papers receiving 14.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders

2000 2.0k citations Joan Massagué, Roger S. Lo et al. Cell profile →
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

2010 1.6k citations Ramin Nazarian, Hubing Shi et al. Nature profile →
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

2012 1.4k citations Antoni Ribas, Roger S. Lo et al. Nature profile →
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

2017 1.3k citations Lu Sun, Willy Hugo et al. profile →
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

2013 715 citations Hubing Shi, Willy Hugo et al. Cancer Discovery profile →
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

2012 470 citations Hubing Shi, Gatien Moriceau et al. profile →
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

2014 427 citations Jennifer Tsoi, Lídia Robert et al. profile →
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

2015 412 citations Willy Hugo, Hubing Shi et al. Cell profile →
Therapy-induced tumour secretomes promote resistance and tumour progression

2015 364 citations Hubing Shi, Xiangju Kong et al. Nature profile →

Peers

Countries citing papers authored by Roger S. Lo

Since Specialization

Citations

This map shows the geographic impact of Roger S. Lo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger S. Lo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger S. Lo more than expected).

Fields of papers citing papers by Roger S. Lo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger S. Lo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger S. Lo. The network helps show where Roger S. Lo may publish in the future.

Co-authorship network of co-authors of Roger S. Lo

This figure shows the co-authorship network connecting the top 25 collaborators of Roger S. Lo. A scholar is included among the top collaborators of Roger S. Lo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger S. Lo. Roger S. Lo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multi-organ landscape of therapy-resistant melanoma 2023 ·Nature Medicine ·Sixue Liu, (unknown), Shirley H. Lomeli, Yan Wang, Xiao Zhang, Zhentao Yang, Raymond J. Lim, Camelia Dumitras, Philip O. Scumpia, (unknown), Gatien Moriceau, Douglas B. Johnson, Stergios J. Moschos, Roger S. Lo	20
2	Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma 2023 ·Cancer Discovery ·(unknown), Xiao Zhang, Sixue Liu, Shirley H. Lomeli, Aayoung Hong, (unknown), Zhentao Yang, (unknown), Agustin Vega-Crespo, Antoni Ribas, Stergios J. Moschos, Gatien Moriceau, Roger S. Lo	53
3	Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance 2022 ·Cancer Discovery ·Zhentao Yang, (unknown), Sixue Liu, Weixian Deng, Shirley H. Lomeli, Gatien Moriceau, James A. Wohlschlegel, Marco Piva, Roger S. Lo	32
4	SPRED1 deletion confers resistance to MAPK inhibition in melanoma 2020 ·The Journal of Experimental Medicine ·Julien Ablain, Sixue Liu, Gatien Moriceau, Roger S. Lo, Leonard I. Zon	21
5	The great debate at “Immunotherapy Bridge 2018”, Naples, November 29th, 2018 2019 ·Journal for ImmunoTherapy of Cancer ·Paolo A. Ascierto, Lisa H. Butterfield, Sandra Demaria, Robert L. Ferris, Gordon J. Freeman, Roger S. Lo, Alberto Mantovani, Paul Nathan, Omid Hamid, Katerina Politi, Igor Puzanov	4
6	Melanoma to Vitiligo: The Melanocyte in Biology & Medicine–Joint Montagna Symposium on the Biology of Skin/PanAmerican Society for Pigment Cell Research Annual Meeting 2019 ·Journal of Investigative Dermatology ·Sancy A. Leachman, Thomas J. Hornyak, Gregory S. Barsh, Boris C. Bastian, Douglas E. Brash, James E. Cleaver, Cynthia D. Cooper, John A. D’Orazio, Mayumi Fujita, Sheri L. Holmen, Arup K. Indra, Kenneth H. Kraemer, I. Caroline Le Poole, Roger S. Lo, Amanda W. Lund, Prashiela Manga, William J. Pavan, Vijayasaradhi Setaluri, (unknown), Molly Kulesz‐Martin	4
7	Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation 2017 ·Cancer Discovery ·Chunying Song, Marco Piva, Lu Sun, Aayoung Hong, Gatien Moriceau, Xiangju Kong, Hong Zhang, Shirley H. Lomeli, Jin Qian, Clarissa C. Yu, Robert Damoiseaux, Mark C. Kelley, (unknown), Philip O. Scumpia, Jeffrey A. Sosman, Douglas B. Johnson, Antoni Ribas, Willy Hugo, Roger S. Lo	109
8	Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma 2017 ·Cancer Discovery ·Aayoung Hong, Gatien Moriceau, Lu Sun, Shirley H. Lomeli, Marco Piva, Robert Damoiseaux, Sheri L. Holmen, Norman E. Sharpless, Willy Hugo, Roger S. Lo	72
9	Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation 2016 ·Nature Cell Biology ·Min Pan, Michael A. Reid, Xazmin H. Lowman, Rajan P. Kulkarni, Thai Q. Tran, Xiaojing Liu, Ying Yang, Jenny E. Hernandez‐Davies, (unknown), Haiqing Li, Willy Hugo, Chunying Song, Xiangdong Xu, Dustin E. Schones, David K. Ann, Viviana Gradinaru, Roger S. Lo, Jason W. Locasale, Mei Kong	276
10	Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction 2015 ·Cancer Cell ·Gatien Moriceau, Willy Hugo, Aayoung Hong, Hubing Shi, Xiangju Kong, Clarissa C. Yu, Richard C. Koya, Ahmed A. Samatar, Négar Khanlou, Jonathan Braun, Kathleen Ruchalski, Heike Seifert, James Larkin, Kimberly B. Dahlman, Douglas B. Johnson, Alain P. Algazi, Jeffrey A. Sosman, Antoni Ribas, Roger S. Lo	237
11	Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma 2014 ·Molecular Cancer ·Deborah J. Wong, Lídia Robert, Mohammad Atefi, Amanda Lassen, (unknown), Michael Cerniglia, Earl Avramis, Jennifer Tsoi, David Foulad, Thomas G. Graeber, Begonya Comin-Anduix, Ahmed A. Samatar, Roger S. Lo, Antoni Ribas	85
12	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy breakdown → 2013 ·Cancer Discovery ·Hubing Shi, Willy Hugo, Xiangju Kong, Aayoung Hong, Richard C. Koya, Gatien Moriceau, Thinle Chodon, Rongqing Guo, Douglas B. Johnson, Kimberly B. Dahlman, Mark C. Kelley, Richard Kefford, Bartosz Chmielowski, John A. Glaspy, Jeffrey A. Sosman, Nicolas van Baren, Georgina V. Long, Antoni Ribas, Roger S. Lo	715
13	A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition 2013 ·Cancer Discovery ·Hubing Shi, Aayoung Hong, Xiangju Kong, Richard C. Koya, Chunying Song, Gatien Moriceau, Willy Hugo, Clarissa C. Yu, Charles Ng, Thinle Chodon, Richard A. Scolyer, Richard Kefford, Antoni Ribas, Georgina V. Long, Roger S. Lo	133
14	Preexisting MEK1 Exon 3 Mutations in V600E/K BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors 2012 ·Cancer Discovery ·Hubing Shi, Gatien Moriceau, Xiangju Kong, Richard C. Koya, Ramin Nazarian, Gulietta M. Pupo, Antonella Bacchiocchi, Kimberly B. Dahlman, Bartosz Chmielowski, Jeffrey A. Sosman, Ruth Halaban, Richard Kefford, Georgina V. Long, Antoni Ribas, Roger S. Lo	75
15	The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms 2012 ·Clinical Cancer Research ·Kim H.T. Paraiso, H. Eirik Haarberg, Elizabeth R. Wood, Vito W. Rebecca, Y. Ann Chen, Yun Xiang, Antoni Ribas, Roger S. Lo, Jeffrey S. Weber, Vernon K. Sondak, (unknown), Amod A. Sarnaik, John M. Koomen, Keiran S.M. Smalley	125
16	Combinatorial Treatments That Overcome PDGFRβ-Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition 2011 ·Cancer Research ·Hubing Shi, Xiangju Kong, Antoni Ribas, Roger S. Lo	184
17	Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations 2011 ·Journal of Translational Medicine ·Franziska Niehr, Erika von Euw, Narsis Attar, Deliang Guo, (unknown), Hooman Sazegar, Charles Ng, John A. Glaspy, Juan A. Recio, Roger S. Lo, Paul S. Mischel, Begonya Comin-Anduix, Antoni Ribas	78
18	Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation breakdown → 2010 ·Nature ·Ramin Nazarian, Hubing Shi, Qi Wang, Xiangju Kong, Richard C. Koya, Hane Lee, Zugen Chen, Mi‐Kyung Lee, Narsis Attar, Hooman Sazegar, Thinle Chodon, Stanley F. Nelson, Grant A. McArthur, Jeffrey A. Sosman, Antoni Ribas, Roger S. Lo	1614
19	Transforming Growth Factor-β Activation Promotes Genetic Context–Dependent Invasion of Immortalized Melanocytes 2008 ·Cancer Research ·Roger S. Lo, Owen N. Witte	24
20	A Smad Transcriptional Corepressor 1999 ·Cell ·David Wotton, Roger S. Lo, Susan Lee, Joan Massagué	482

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact